LGD 3303 Tablets
LGD 3303 is offered in 2 variants: 12mg per tablet for 30 tabs and 60 tabs , totaling 360 mg or 720mg of LGD 3303 respectively.
LGD 3303 is a research compound being investigated for its potential of binding onto the androgenic receptors in muscles and bones. Different from anabolic compounds that bind onto all the receptors in the body, including reproductive organs, LGD 3303 may possibly bind to muscle or bone receptors only.
Recent studies have tested the effect of daily oral doses of LGD-3303 on strength and bone density of ovariectomized, osteopenic rats, a prevalent model used to evaluate post-menopausal osteoporosis.
The studies found LGD-3303 to be a powerful and highly selective androgen receptor full agonist in skeletal muscle, a target tissue well-known for androgen action. By comparison, in the sebaceous glands and prostate, the compound is a much weaker partial agonist. The ability of effective, pharmacological LGD-3303 to spare these non-target tissues provides a novel and potentially safer treatment for osteoporosis.
|CAS Number||917891-35-1, 1196133-39-7|
|Molar Mass||342.75 g·mol−1|